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Abstract
Background: Malaria and anaemia are the leading causes of morbidity and mortality in children in sub-Saharan Africa. We
have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus
amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in Ghana.
Methods: 2451 children aged 3–59 months from 30 villages were individually randomised to receive placebo or artesunate
plusamodiaquine(AS+AQ)monthlyor bimonthly, orsulphadoxine-pyrimethamine(SP)bimonthlyovera periodof sixmonths.
The primary outcome measures were episodes of anaemia (Hb,8.0 g/dl) or malaria detected through passive surveillance.
Findings: Monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% CI: 63%, 74%) and anaemia
by 45% (95% CI: 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% CI:
14%,33%) and anaemia by 30% (95% CI: 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of
malaria by 17% (95% CI: 6%, 27%) and anaemia by 32% (95% CI: 7%, 50%) compared to placebo. There were no statistically
significant reductions in the episodes of all cause or malaria specific hospital admissions in any of the intervention groups
compared to the placebo group. There was no significant increase in the incidence of clinical malaria in the post
intervention period in children who were .1 year old when they received IPTc compared to the placebo group. However
the incidence of malaria in the post intervention period was higher in children who were ,1 year old when they received
AS+AQ monthly compared to the placebo group.
Interpretation: IPTc is safe and efficacious in reducing the burden of malaria in an area of Ghana with a prolonged, intense
malaria transmission season.
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Introduction
In Africa, malaria causes over a million deaths and many
millions of episodes of illness in children less than five years of age
each year [1,2]. Intermittent preventive treatment in children
(IPTc), which involves administration of antimalarial drugs at pre-
defined time intervals to children irrespective of whether or not
they are infected with malaria, is a promising new approach to
reducing the burden of malaria in children. IPTc using
sulphadoxine-pyrimethamine (SP) alone or in combination with
a single dose of artesunate (AS) has been shown to be efficacious in
reducing the incidence of malaria in areas of Mali [3] and Senegal
[4] with a short malaria transmission season. The ability of IPTc to
reduce the burden of malaria in areas with a more prolonged
transmission season is not known. Furthermore, resistance to SP is
increasing and hence there is a need to find alternative drugs or
drug combinations that could be used for IPTc. In this paper, we
report the results of a randomized controlled trial of IPTc using SP
or artesunate+amodiaquine (AS+AQ) in an area with an extended
period of transmission in Ghana.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
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This study was carried out in Hohoe district, Ghana. The
transmission of malaria in the study area is intense with two
seasonal peaks. The major wet season lasts from April to July and
the minor one from September to November. The entomological
inoculation rate during the study period was ,65 infective bites
per person per year (unpublished data). Plasmodium falciparum is the
dominant malaria parasite in the area and remains sensitive to SP
and AQ. A study undertaken in 480 children aged 3–59 months
with symptomatic malaria at the time of the trial, described in
another publication, showed that the drugs used in this trial of
IPTc were efficacious. The polymerase chain reaction (PCR)
corrected parasitological failure rate by day 28 was 2.3% for
AS+AQ and 6.8% for SP. However, the re-infection rate by day
28 was slightly higher: 16% for AS+AQ and 19% for SP [5].
Enrolment and randomization
From a sampling frame of all villages and communities in the
district, the number of children living in each community was
determined from the 2000 census. Thirty communities with the
required number of children for the trial (2125) were randomly
selected by probability proportional to the number of children
living in each community. Several meetings were held with the
health authorities and with community leaders and care givers in
each selected community to explain the study objectives and
procedures. Caretakers of all children aged 3 to 59 months in the
selected communities were invited to a central point in the
community to allow screening and enumeration of their children.
Each of the four treatment groups was sub-divided into three
sub-groups to reduce the chance of accidental unblinding through
recognition by trial staff of outcomes in one particular group.
Thus, eligible children were randomized into 12 groups. The
number of children to be allocated to each of the 12 subgroups was
determined in each village/cluster by dividing the total number of
eligible children living in each village (rounded to multiples of 12)
by 12. For each village, the required number of tokens, marked
with a study code, was prepared and mixed in a large container.
Caretakers of eligible children who reported on the enrolment day
picked a token from the container and their child was then
allocated to the treatment group indicated by the token.
After obtaining written, informed consent, demographic
information and data on socio-economic status, including the
use of bednets, were collected. A clinical examination was
conducted and anthropometric measurements were made. A
study identity card was given to the parents of each child and they
were advised to bring their child to a study health facility if the
child became ill.
Sample size
Sample size was estimated on the basis of the following
assumptions: (1) the incidence of anaemia (Hb,8.0 g/dl) would be
0.28/child/year in the SP bimonthly group, 0.23/child/year in
the AS+AQ bimonthly group and 0.18/child/year in the AS+AQ
monthly group respectively (incidence rates for the placebo and SP
groups are based on the findings of a pilot trial conducted in the
study area previously); (2) loss to follow up would be 10%; (3) the
study needed to have 90% power to detect a 33% difference
between the SP bimonthly and AS+AQ monthly groups (likely to
be the least and most effective interventions respectively) at a 5%
significance level. The estimated sample size needed to meet these
requirements was 2125 children (531 per arm). We also assumed
that the incidence of clinical malaria would be 0.5 /child/year in
the placebo group, 0.35/child/year in the SP bimonthly group,
0.25/child/year in the AS+AQ bimonthly group and 0.20/child/
year in the AS+AQ monthly group. A sample size of 2125 children
would have 99% power at a 5% level of significance to detect a
43% difference in the incidence of malaria between the SP
bimonthly and AS+AQ monthly groups. Since more children were
identified in the selected villages than needed to meet the required
sample size and because the caretakers were eager to enroll their
children in the study, a total of 2451 children (613 per arm) were
enrolled.
Study drugs and drug administration
Study drugs and matching placebos were supplied by
Kinapharma Limited, Accra, Ghana. Their quality was confirmed
at the London School of Hygiene & Tropical Medicine by
dissolution and content assays for AQ and content assays for AS
and SP. One of the investigator (MK) and six ‘‘drug-packers’’
packed the study drugs for each child in well labeled envelopes
according to age and study group using the randomisation list for
each village. MK and the ‘‘drug-packers’’ did not take any part in
assessing adverse events or in measuring study outcomes.
All doses of the study drugs were administered to children by
community-based volunteers. The volunteers were selected by the
mothers/guardians of the children in each community to
administer drugs and collect information on morbidity and
adverse events and were paid an allowance of $10 a month for
the periods during which they worked. Tablets were crushed and
mixed with water. Children aged 3–5 months received a quarter of
a tablet , those aged 6–11 months half a tablet, those aged 12–23
months three quarters of a tablet (3/4) and those aged 24 months
and above received one tablet each of SP, co-formulated AS+AQ
or placebo. Children received study drugs every 28 days on six
occasions.
Follow-up
Field workers visited study children to solicit any adverse events
7 to 10 days after administration of study drugs. Reported adverse
events were investigated and managed by a study clinician. Field
workers visited the children once a week during the period of drug
administration to enquire about their health and completed a
morbidity form if a child had any illness. If a child had a history of
fever or vomiting within the past 48 hours the parents were
advised to take their child to the nearest health facility for
examination and treatment.
A passive surveillance system to monitor malaria and anaemia
in study children throughout the study period was set up in the
district hospital and in 21 health centres in the study area. If a
child who presented at one of these facilities had fever or any
features suggestive of malaria, a finger prick blood sample was
collected for malaria parasite examination before treatment was
given. Blood slides were read at the respective health facility to
decide on treatment and read again in a central laboratory to
confirm the diagnosis. Children with proven or presumptive
malaria were treated with oral quinine according to the Ministry
of Health (MOH) treatment guidelines.
Cross sectional surveys were carried out at the end of the
intervention period (November 2005), at the end of the following
dry season (April 2006) and at the end of the following rainy
season (November 2006). During these surveys, temperature,
weight, height and mid upper arm circumference were measured
and a finger prick blood sample was collected for determination of
malaria parasitaemia, haemoglobin (Hb), and markers of SP
resistance. Venous blood samples were collected from a sub
population of enrolled children for determination of G-6-PD
deficiency and the presence of haemoglobin C and S. This was
done by sampling children who were due for blood donation at the
Malaria IPT Trial in Children
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sectional survey. A household survey was carried out in August
2006 to determine ITN use.
Hb was measured for children attending a clinic with an axillary
temperature of .=37.5uC or a history of fever or vomiting during
the past two days. Children found to have an Hb,6.0 g/dl were
referred to the district hospital for management.
Laboratory methods
Laboratory assistants, masked to study group, examined thick
blood films for parasitaemia. A sample was considered negative
only after 200 high power fields had been read. Parasite counts
were converted to parasites per micro liter (ml), assuming a white
blood cell count of 8000 leukocytes per ml of blood. If there was a
discrepancy in the findings in a slide between the two initial
technicians (positive or negative or a 50% or more difference in
parasite density) a third, more senior microscopist read the slide
and his reading was deemed to be the correct reading. A senior
microscopist from the Noguchi Memorial Institute of Medical
Research (NMIMR, Ghana) examined all the positive blood films
and a 20% random sample of negative blood slides for quality
control. Haemoglobin was measured using Hemocue H Photom-
eter (Leo Diagnostics, Sweden).
Phenotypic evidence for Glucose-6-Phosphate Dehydrogenase
(G-6-PD) deficiency was determined by the methaemoglobin
reduction method (products of SIGMA Diagnostics, St Louis
USA). Sickle cell genotyping was done by haemoglobin electro-
phoresis.
Data management
Data from participants were recorded on specified forms and
were checked by field supervisors and data manager for
consistency and accuracy. All data were entered twice into a
database using EPI Data software. The accuracy of data input was
checked and validated using customized validation programmes.
The cleaned data were converted to Stata version 8 file by a
statistician (Stata Corporation, Texas, USA) prior to analysis.
Statistical analyses
The primary trial endpoints were the incidences of anaemia,
defined as an Hb,8.0 g/dl and severe anaemia, defined as an
Hb,5.0 g/dl. Malaria anaemia was defined as anaemia, defined
as above, plus malaria parasitaemia. Clinical malaria was defined
as a reported history of fever within 48 hours or a measured
temperature of 37.5uC or greater with a positive blood slide
showing asexual forms of P. falciparum at any level of parasitaemia.
An additional case definition for malaria of fever or history of fever
plus a parasite density of greater than 7000/ml was also used.
Severe malaria was defined as a hospital admission which met the
above definitions of malaria. Any symptom or sign that first
appeared or increased in severity within seven days of drug
administration was defined as an adverse event. Time at risk of
primary and secondary endpoints started at the time of
enrollment. Person time at risk for anaemia and malaria was
calculated by subtracting the date of enrolment from the date of
exit from the study. The date of exit for children who died was the
date of death. The date of exit for children who were lost to follow
Figure 1. Trial Profile
doi:10.1371/journal.pone.0004000.g001
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with the passive or active surveillance systems. Children who
moved temporarily out of the study area but returned to take some
of the courses of treatment remained as part of the study cohort.
Four weeks per episode was subtracted from the person time at risk
for children who had an episode of malaria that was treated with
an effective antimalarial. Children who had an episode of anaemia
were not sensored from the person time at risk because it is not
clear how long a child will be risk free after an episode of anaemia.
Analysis of the primary and secondary outcomes was carried out
on an intention-to-treat basis in which all randomised who received
thefirstdose ofIPTcchildrenwereincludeduntil completion orexit
from the study due to withdrawal of consent, loss to follow up or
death. Proportions of outcomes were analysed using chi-square test.
Differences in means were calculated using t test for comparison of
two means. All analyses were done with STATA software version
8.2. The incidence rate ratio (IRR) was estimated using the placebo
group as the comparator. Protective efficacy was calculated as
(12IRR)6100. The Kaplan- Meier method was used to plot the
time to the first episode of anaemia and malaria attack after the start
of the intervention. Poisson regression was used to estimate the
protective efficacy of the IPTc drugs adjusted for the effect of Hb
type, G6PD deficiency and bednet use in a subset of children who
had data on Hb type and G6PD status.
Ethical approval
The study was approved by ethical committees of the Ghana
Health Service/Ministry of Health (GHS/MOH) and the London
School of Hygiene & Tropical Medicine. A Data Safety and
Monitoring Board (DSMB) was established to monitor the trial.
The DSMB approved the study protocol and its analytical plan.
Role of the funding source
The sponsor had no role in the study design, data collection,
data analysis, data interpretation or writing of the report. The
corresponding author had full access to all the data in the study
and had final responsibility for the decision to submit for
publication.
Results
Two thousand, seven hundred and fifty-five children were
screened in May 2005 and 2602 (94%) were eligible for inclusion
in the trial. However, only 2451 (89%) reported for enrolment and
received the first IPTc dose. The number of children assigned to
each group (650 to placebo, 613 to SP, 562 to AS+AQ bimonthly
and 626 to AS+AQ monthly) and the follow up rates achieved in
each group are shown in Figure 1. The follow up rate up to six
months was high and comparable between the study groups (range
92%–95%). Mean age was slightly lower in the AS+AQ bimonthly
group than in the other three groups (Table 1). There were no
statistically significant differences between groups in bednet use or
in anthropometric indices at enrolment. Overall, 87.7% of the
children were highly adherent to treatment (received all six
courses), 10.6% moderately adherent (received 3–5 courses) and
1.7% poorly adherent (received ,3 courses). There was no
statistically significant difference in the rate of adherence between
the study groups (p.0.05).
Anaemia and malaria during the intervention period
During the six months of the intervention period, the incidence
of anaemia, the primary trial endpoint, was significantly lower in
all IPTc groups compared to the placebo group (Table 2).
Protective efficacy against anaemia adjusted for the effect of age at
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PLoS ONE | www.plosone.org 5 December 2008 | Volume 3 | Issue 12 | e4000enrolment and bednet use was 45% in the AS+AQ monthly group
(95% CI: 25%, 60%), 31% in the SP bimonthly group (95% CI:
6%, 49%) and 32% in the AS+AQ bimonthly group (95% CI: 7%,
50%). A Kaplan-Meier survival plot (Figure 2a,b and c) shows that
the time to first episode of anaemia was significantly higher in SP
monthly, AS+AQ monthly and AS+AQ bimonthly groups
compared to the placebo.
The incidences of clinical malaria in children attending an OPD
with any parasitaemia or high density parasitaemia during the
intervention period were significantly lower in all three IPTc
groups compared to the placebo group (Table 2). During the
intervention period, the protective efficacy against all episodes of
clinical malaria adjusted for the effect of age at enrolment and
bednet use was 69% (95% CI: 63%, 74%) for the AS+AQ monthly
group, 24% for the SP group (95% CI: 14%, 33%) and 17% for
the AS+AQ bimonthly group (95% CI: 6%, 27%). Protective
efficacy against clinical malaria with high density parasitaemia
adjusted for the effect of age at enrolment and bednet use was 71%
(95% CI: 64%, 76%) for the AS+AQ monthly group, 31% for the
SP group (95% CI: 20%, 41%) and 20% for the AS+AQ
bimonthly group (95% CI: 8%, 31%) (Table 2). The time to first
or only episode of malaria unadjusted for the effect of age at
enrolment was significantly higher in all three intervention groups
compared to the placebo group (Figure 3a,b and c).
The differences in OPD attendance, all cause and malaria
specific admissions to the hospital between the intervention groups
and the placebo group were not statistically significant. In the
subset of 529 children for whom there were data on Hb genotype
and G6PD status, the protective effect against malaria and
anaemia adjusted for the effect of age, bednet use, Hb type and
G6PD status was statistically significant in the AS+AQ monthly
group compared to the placebo group (Table 3).
Anaemia and malaria during the post-intervention period
There were very few cases of anaemia or malaria in children in
any of the groups during the post-intervention dry season and
there were no statistically significant differences between the
groups (Table 4). During the post intervention rainy season, the
incidence of clinical malaria with any parasitaemia or high density
parasitaemia was slightly higher in the three IPTc groups than in
the placebo group but these differences were not statistically
significant (Table 5). However there was a statistically significant
increased risk of malaria in the post intervention period in children
in the AS+AQ monthly group, the most effective protective
regimen, who were under the age of one year when they received
IPTc (Table 6).
Cross-sectional surveys
The prevalence of malaria parasitaemia was significantly lower
in the AS+AQ monthly group at the end of the intervention period
but it was significantly higher at the end of the dry season
following the intervention period compared to the placebo group
(Table 7). There was no significant difference in the prevalences of
anaemia or gametocytaemia between the study groups at the end
Figure 2. Figure 2a: Kaplan-Meier survival estimates for time to first or
only episode of anaemia during the intervention period between
placebo and SP groups. Figure 2b: Kaplan-Meier survival estimates for
time to first or only episode of anaemia during the intervention period
between placebo and AS+AQ bimonthly groups Figure 2c: Kaplan-
Meier survival estimates for time to first or only episode of anaemia
during the intervention period between placebo and AS+AQ monthly
groups
doi:10.1371/journal.pone.0004000.g002
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intervention period.
Adverse events
Adverse events were reported slightly less frequently in each of
the three IPTc groups compared to the placebo group throughout
the intervention period (5.6 % vs 5.9%). Diarrhoea, vomiting,
drowsiness and abdominal pains were the most frequently
reported symptoms in both IPTc and placebo groups. The
number of children who reported at least one adverse event or any
specific adverse event did not differ significantly between the study
groups. Ten deaths (6 deaths due to malaria) occurred during the
intervention period and 16 deaths (11 deaths due to malaria)
occurred during the 12 month post intervention period. There was
no significant difference in the numbers of deaths between the
IPTc and placebo groups (8 in the placebo, 8 in the AS+AQ
monthly, 5 in the AS+AQ bimonthly and 5 in the SP bimonthly
groups) respectively.
Discussion
The protective effect of IPTc against malaria and anaemia
observed in our study is consistent with findings from Senegal and
Mali. Monthly SP+AS IPTc had a protective efficacy against
clinical attacks of malaria of 86% (95% CI: 81%–90%) in Senegal
[4] and bimonthly SP IPTc had a protective efficacy against
clinical attacks of malaria of 40% (95% CI: 25–51%) among 6
months to 10 year old children in Mali [3]. We chose a two-
monthly regimen because we were concerned about the
practicality of administering SP monthly for six months in a
routine national malaria control programme setting and because
we have evidence from a SP IPTi trial in Ghana that SP provides
about six weeks prophylaxis when used for IPT [6] We include an
artemisinin in the drug combination for IPTc for two reasons.
Firstly, an artemisinin will reduce the parasite load rapidly in
children with parasitaemia and thus reduce the likelihood of
resistance emerging to the partner drug and secondly it will clear
gamtocytes and reduce the likelihood of transmission of any
resistant parasites selected by the drug administration. Subsequent
studies in Senegal [7] have shown that amodiaquine+SP is a more
efficacious combination than AS+AQ but these data were not
available when the Hohoe study was planned.
Our study has shown that even in an area with up to six months
of intense transmission, monthly IPTc with AS+AQ has
substantial benefits in reducing the incidence of malaria and
anaemia. The combined results of studies of IPTc suggests that for
drugs such as SP and AQ monthly treatment is probably necessary
to achieve a high level of protection. Although IPTc was effective
in reducing episodes of anaemia detected at a clinic we did not find
a significant reduction in the prevalence of anaemia at the end of
the IPTc intervention period. This is consistent with the
observation in Senegal and with the findings of IPTi studies in
Tanzania [8] and in Ghana [9]. This could be due to the fact that
the study children were closely monitored and all episodes of
Figure 3. Figure 3a: Kaplan-Meier survival estimates for time to first
or only episode of malaria during the intervention period between
placebo and SP groups. Figure 3b: Kaplan-Meier survival estimates for
time to first or only episode of malaria during the intervention period
between placebo and AS+AQ bimonthly groups. Figure 3c: Kaplan-
Meier survival estimates for time to first or only episode of malaria
during the intervention period between placebo and AS+AQ monthly
groups
doi:10.1371/journal.pone.0004000.g003
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transfusion in the case of severe anaemia.
We found that the prevalences of G-6-PD deficiency and
haemoglobin S and C in the study area were similar to those
reported from the northern and central parts of Ghana [10,11].
IPTc was well tolerated by children with G-6-PD deficiency or
haemoglobin S or C and we did not observe any episode of
haemolysis following the administration of SP to children with G-
6-PD deficiency. The study has shown that IPTc provides
protection against clinical malaria and anaemia for both children
with normal or deficient G-6-PD and those carrying haemoglobin
So rC .
We did not find any significant increase in the incidence of
clinical episodes of malaria associated with parasitaemia at any
density or at high density parasitaemia in the rainy season
following IPTc intervention period in older children (12–59
months), consistent with the results of studies done in Mali and
Senegal. However, we found a slight increase in the incidence of
clinical malaria associated with parasitaemia of any density or high
density parasitaemia in infants aged 3–11 months in the IPTc
treatment groups during the rainy season following the IPTc
intervention period. The overall incidence of malaria was lower
during the rainy season following the intervention than during the
intervention period (Figure 4). The reason for this reduction in the
incidence of malaria during the post intervention period is not
clear. We speculate that the high coverage of IPTc, effective
treatment and an increase in the use of ITNs in the study area may
have led to a reduction in the transmission of malaria. Overall, our
study does not suggest that there is a significant risk of rebound of
malaria if IPTc is given for just one year. It will be important to
determine whether this is also the case if IPTc is given for a longer
period.
SP, AS and AQ were well tolerated and no serious adverse
events attributable to the study drugs were reported during the
study period. The incidence of mild adverse events such as fever,
general weakness, vomiting, diarrhea, abdominal pain and cough
were similar in the placebo and IPTc groups. These symptoms and
signs were probably due to in a large part to common childhood
illnesses and not related to the administration of the IPTc drugs.
Nevertheless, some mothers/guardians withdrew their children
because of perceived adverse events associated with drug
administration. This is a concern if IPTc is to be rolled out on a
national scale. Mothers’ main concerns were vomiting and
drowsiness after drug administration. Clear health education
messages, including information on potential adverse events and
the means to overcome these events, would need to be delivered to
IPTc providers and the target population in order to achieve an
effective coverage of IPTc in a routine programme setting.
A recent multicentre pharmacokinetics study showed that
children aged 2–5 years should be treated with 1 g sulphadoxine
and 50 mg pyrimethamine to achieve drug concentrations
equivalent to those needed in adults for treatment of uncompli-
cated malaria [12]. The doses of SP, AS, and AQ in our study
were based on age not on exact weight. This could have resulted in
some children receiving lower than recommended doses of SP
reducing the protective efficacy of IPTc and some children
receiving more than recommended dose of SP. However, in a
community volunteer based delivery system an age based dose
regimen is easier to implement than a weight-based dose regimen.
Thus our study reflects the protective efficacy of age based dose of
IPTc in a community based delivery system
Potential weaknesses of this study are that there was an
imbalance in the number of children allocated to one study group
for reasons that we have not been able to explain. We have
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PLoS ONE | www.plosone.org 9 December 2008 | Volume 3 | Issue 12 | e4000explored all possible reasons as to why this might have occurred
but have not been able to find any rational explanation other than
chance. Since we have adjusted the protective efficacies for the
effect of age at enrolment and bednet use, the potential effect
modifiers, it is unlikely that this imbalance in the number of
children between the groups would have biased our observation.
During the intervention period, losses to follow up were very low.
Because there was no active follow up during the post intervention
period we cannot be sure how many children had moved out for
substantial periods during this period and we had, therefore, to
assume that those who took part in the last cross sectional survey
had remained in the study area throughout the follow up period.
Approximately 40% of children enrolled in each group did not
attend the last cross sectional survey but there was no difference in
the response rate between the four study groups and this loss to
follow up is unlikely to have biased our observation.
We found that adherence to IPTc drugs delivered through
community-based volunteers was similar to that achieved by
project staff in Senegal (88% versus 91%). Delivering IPTc
through community-based volunteers has advantages. They are
resident in the community, making drug administration easy, they
can give a repeat dose if a child vomits and can remind mothers/
guardians to complete the course of treatment. However,
sustaining the motivation of the volunteers for long periods is
difficult. Delivering IPTc through the routine health delivery
system is an attractive option because medically qualified staff are
Table 6. Comparison of clinical malaria with any parasitaemia during the rainy season following the IPTc intervention between
infants and older children
Age group Treatment group Events PWAR
1 Rate* Protective Efficacy (95% CI) p-value
15–23 months (Formerly 3–11
moths)
Placebo 6 1629 0.37
SP bimonthly 16 2156 0.74 250% (234%, 84%) 0.070
AS+AQ bimonthly 13 2108 0.62 240% (268%, 81%) 0.152
AS+AQ monthly 21 2152 0.98 262% (23%, 88%) 0.014
24–71 months (Formerly 12–59
months)
Placebo 40 10038 0.40
SP bimonthly 43 8428 0.51 222% (223%, 51%) 0.131
AS+AQ bimonthly 28 7470 0.37 6% (256%, 44%) 0.405
AS+AQ monthly 39 9076 0.43 27% (248%, 42%) 0.369
PWAR
1- person weeks at risk;
*Per 100 child years at risk; Protective efficacy calculated on the basis of incidence rates (12IRR)6100.
doi:10.1371/journal.pone.0004000.t006
Table 7. Findings at cross-sectional surveys at one, six and twelve months following IPTc intervention (per protocol analysis)
Outcome
Placebo
n( % )
SP bimonthly
n (%) p-value
AQ+AS
bimonthly n (%) p-value
AQ+AS
monthly n (%) p-value
End of intervention period
Anaemia Hb,8.0 g/dl 60 (10.2) 69 (12.5) 0.196 67 (14.4) 0.143 52 (9.3) 0.491
Mean Hb (SD) 9.3 (1.33) 9.2 (1.33) 0.459
{ 9.2 (1.33) 0.186
{ 9.4 (1.22) 0.289
{
Any parasitaemia 114 (19.6) 88 (16.3) 0.152 102 (20.0) 0.852 27 (4.7) ,0.001
Parasite density .7000/ml 40 (6.9) 41 (7.6) 0.642 41 (8.1) 0.458 8 (1.4) ,0.001
Gametocytaemia 6 (1.0) 1 (0.2) 0.072 2 (0.4) 0.218 4 (0.7) 0.545
End of dry season post intervention
Anaemia Hb,8.0 g/dl 34 (7.1 ) 33 (7.5 ) 0.868 30 (7.5 ) 0.905 43 (9.3) 0.243
Mean Hb (SD) 9.26 (1.04) 9.37 (1.96) 0.338
{ 9.18 (0.99) 0.231
{ 9.26 (1.15) 0.969
{
Any parasitaemia 30 (6.2) 40 (0.0) 0.365 38 (9.5) 0.067 48 (10.4) 0.035
High density parasitaemia 10 (2.1) 16 (3.6 ) 0.158 10 (2.5) 0.685 14 (3.0) 0.357
Gametocytaemia 5 (1.0) 3(0.7) 0.481 1 (0.2 ) 0.211 5 (1.1) 0.745
End of the rainy post intervention
Anaemia Hb,8.0 g/dl 47 (12.0) 42 (11.9) 0.987 47 (14.7) 0.405 36 (9.57) 0.281
Mean Hb (SD) 9.29 (1.22) 9.35 (1.33) 0.330
{ 9.48 (4.88) 0.327
{ 9.32 (3.10) 0.805
{
Any parasitaemia density 155 (39.7) 138 (39.2) 0.532 129 (40.4) 0.856 158 (42.0) 0.579
High density parasitaemia 42 (10.7) 31 (8.8) 0.272 32 (10.0) 0.637 46 (12.2) 0.538
Gametocytaemia 4 (1.0) 0 0.051 4 (1.25) 0.815 4 (1.1) 0.959
{p-values from t test comparing two means
doi:10.1371/journal.pone.0004000.t007
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PLoS ONE | www.plosone.org 10 December 2008 | Volume 3 | Issue 12 | e4000available to monitor any adverse events. However, in Ghana, only
50% of children aged between 12 and 23 months use growth
monitoring services at established health posts. This means that it
would be difficult to achieve a high coverage of IPTc using this
route. A comparison these two modes of delivery has recently been
undertaken in the Jasikan region of Ghana, an area adjacent to the
one where the current study was done, and the results of this trial
will be reported shortly.
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